Sangamo Therapeutics, Inc. (SGMO) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SGMO Revenue Growth
Revenue Breakdown (FY 2024)
SGMO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
SGMO Revenue Analysis (2013–2024)
As of May 7, 2026, Sangamo Therapeutics, Inc. (SGMO) generated trailing twelve-month (TTM) revenue of $32.9 million, reflecting significant decline in growth of -98.8% year-over-year. The most recent quarter (Q3 2025) recorded $581,000 in revenue, down 96.8% sequentially.
Looking at the longer-term picture, SGMO's 5-year compound annual growth rate (CAGR) stands at -10.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $176.2 million in 2023.
Revenue diversification analysis shows SGMO's business is primarily driven by License (97%), and Service (3%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CRSP (-88.9% YoY), BEAM (+120.0% YoY), and PRME (+55.3% YoY), SGMO has underperformed the peer group in terms of revenue growth. Compare SGMO vs CRSP →
SGMO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SGMOCurrent | $33M | -98.8% | -10.8% | -179.9% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +120.0% | +466.3% | -274.6% | |
 PRME | $5M | +55.3% | -2.3% | -4498.1% |
SGMO Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $57.8M | -67.2% | $57.8M | 100.0% | $-103,969,000 | -179.9% |
| 2023 | $176.2M | +58.3% | $176.2M | 100.0% | $-274,005,000 | -155.5% |
| 2022 | $111.3M | +0.5% | $99.2M | 89.1% | $-201,281,000 | -180.8% |
| 2021 | $110.7M | -6.3% | $110.7M | 100.0% | $-183,337,000 | -165.6% |
| 2020 | $118.2M | +15.4% | $-62,455,000 | -52.8% | $-129,551,999 | -109.6% |
| 2019 | $102.4M | +21.3% | $-43,494,000 | -42.5% | $-105,180,000 | -102.7% |
| 2018 | $84.5M | +131.0% | $-30,414,000 | -36.0% | $-77,150,000 | -91.4% |
| 2017 | $36.6M | +88.6% | $-29,161,000 | -79.7% | $-56,361,000 | -154.1% |
| 2016 | $19.4M | -51.0% | $-46,229,000 | -238.4% | $-72,559,000 | -374.2% |
| 2015 | $39.5M | -13.8% | $-27,589,000 | -69.8% | $-46,856,000 | -118.5% |
See SGMO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGMO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SGMO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSGMO — Frequently Asked Questions
Quick answers to the most common questions about buying SGMO stock.
Is SGMO's revenue growth accelerating or slowing?
SGMO revenue declined -98.8% year-over-year, contrasting with the 5-year CAGR of -10.8%. TTM revenue fell to $33M. This reverses the prior growth trend.
What is SGMO's long-term revenue growth rate?
Sangamo Therapeutics, Inc.'s 5-year revenue CAGR of -10.8% reflects the variable expansion pattern. Current YoY growth of -98.8% is below this long-term average.
How is SGMO's revenue distributed by segment?
SGMO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.